今年1月，艾伯维斥资超10亿美元引进先声再明自主研发的靶向GPRC5D/BCMA/CD3三特异性T细胞接合器（TCE）SIM0500 ...

2024年，两款TCE药物全球首次获得批准上市。安进开发的DLL3/CD3 TCE在5月获美国FDA加速批准，用于一线治疗广泛期小细胞肺癌成人患者，为首款用于治疗实体瘤的双特异性TCE。再生元开发的CD20/CD3靶向TCE Odronextamab于8月份获EMA批准上市，首次获批准用于治疗复发或难治性（R/R）滤泡性淋巴瘤或R/R弥漫性大B细胞淋巴瘤成年患者。

肿瘤治疗始终面临着诸多挑战，提高治疗的特异性、疗效并降低副作用是关键目标。免疫疗法作为一种新兴的治疗手段，在过去几十年中得到了广泛研究。嵌合抗原受体 T（CAR-T）细胞疗法在血液系统恶性肿瘤治疗中取得了显著成效，但存在生产成本高昂、制备过程复杂以及潜在慢性毒副作用等问题。

中国国家药监局药品审评中心 (CDE)官网最新公示，诺华 (NVS.US)申报的1类新药PIT565获得一项新的临床试验默示许可，拟开发治疗系统性红斑狼疮 (SLE)。公开资料显示，这是诺华在研的一款抗CD3/CD19/CD2的三特异性抗体，此前已经在中国获批针对B细胞恶性肿瘤的IND。

S3). Immunohistochemical analysis showed a dense lymphocytic infiltration of the lamina propria positive for T-cell receptor (TCR) α, CD3, CD4, and granzyme B but which did not express TRBC1 ...

1Department of Obstetrics and Gynecology, Peking University Third Hospital, China 2Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China. 3Biobank, Peking ...

The DALI tool facilitates linking TCR clonotype information to functional properties ... BioLegend), anti-CD4 (BUV395, BD Biosciences) and anti-CD3 (BUV737, BD Biosciences), anti-Ki-67 (BV786, BD ...

Founded in 1999, TCR is today a major business-to-business service provider in the GSE sector. TCR implements the rental, repair and maintenance of Ground Support Equipment (GSE) and owns over 50,000 ...

The Belo Horizonte street race will join the 2025 TCR South America calendar on August 16-17 in Brazil. “Our presence at the BH Stock Festival is another step towards the growth and consolidation of ...

Functionally bivalent non-covalent Fab dimers (Bi-Fabs) specific for the TCR/CD3 complex promote CD3 signaling on T cells. While comparing functional responses to stimulation with Bi-Fab, F(ab’)2 or ...